Nrf2 overexpression starts out playing a protective role in cancer, but ultimately encourages disease progression and metastasis, while mutations in Keap1 have been linked to a poor prognosis in individuals with advanced NSCLC receiving treatment [10]. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.